Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia

The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized the treatment of chronic myeloid leukemia (CML). However current unmet clinical needs include combating activation of additional survival signaling pathways in persistent leukemia stem cells after long-term TKI ther...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Laidlaw, Kamilla M.E., Berhan, Samuel, Liu, Suhu, Silvestri, Giovannino, Holyoake, Tessa L., Frank, David A., Aggarwal, Bharat, Bonner, Michael Y., Perrotti, Danilo, Jørgensen, Heather G., Arbiser, Jack L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239504/
https://ncbi.nlm.nih.gov/pubmed/27438151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10541
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge